C4 Therapeutics (CCCC) Invested Capital: 2019-2025
Historic Invested Capital for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $154.4 million.
- C4 Therapeutics' Invested Capital fell 36.37% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.4 million, marking a year-over-year decrease of 36.37%. This contributed to the annual value of $216.0 million for FY2024, which is 12.24% down from last year.
- C4 Therapeutics' Invested Capital amounted to $154.4 million in Q3 2025, which was down 11.29% from $174.1 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Invested Capital high stood at $416.4 million for Q2 2021, and its period low was $154.4 million during Q3 2025.
- Moreover, its 3-year median value for Invested Capital was $242.7 million (2024), whereas its average is $224.4 million.
- In the last 5 years, C4 Therapeutics' Invested Capital skyrocketed by 408.32% in 2021 and then slumped by 36.37% in 2025.
- C4 Therapeutics' Invested Capital (Quarterly) stood at $389.6 million in 2021, then fell by 22.82% to $300.7 million in 2022, then dropped by 18.16% to $246.1 million in 2023, then fell by 12.24% to $216.0 million in 2024, then plummeted by 36.37% to $154.4 million in 2025.
- Its Invested Capital was $154.4 million in Q3 2025, compared to $174.1 million in Q2 2025 and $195.1 million in Q1 2025.